Back to today’s briefing

Story perspectives

DoxyPEP Cuts STI Rates Dramatically in New Study

1/8/2025

36 7

Summary

Story summary

A groundbreaking study in JAMA Internal Medicine reveals that doxycycline postexposure prophylaxis (doxyPEP) is a game-changer in the fight against sexually transmitted infections (STIs). Among 11,551 adults on HIV PrEP, chlamydia rates plummeted from 9.6% to 2.0%, gonorrhea from 10.2% to 9.0%, and syphilis from 1.7% to a mere 0.3%, showcasing its vital role in public health.

1 of 1

Story summary

A groundbreaking study in JAMA Internal Medicine reveals that doxycycline postexposure prophylaxis (doxyPEP) is a game-changer in the fight against sexually transmitted infections (STIs). Among 11,551 adults on HIV PrEP, chlamydia rates plummeted from 9.6% to 2.0%, gonorrhea from 10.2% to 9.0%, and syphilis from 1.7% to a mere 0.3%, showcasing its vital role in public health.